Immunoglobulin A Targeting on the N-Terminal Moiety of Viral Phosphoprotein Prevents Measles Virus from Evading Interferon-β Signaling. by Yang, Y et al.
IgA targeting on N-terminal moiety of viral phosphoprotein prevents measles virus from evading interferon beta signaling
Yi Yang2, 4, #, Dihan Zhou1, 2, #, Bali Zhao2, 4, Yuan Cao2, 4, Jie Yu2, 4, Hu Yan2, 4, Wei Zhao2, 4, Ejuan Zhang2, Jingyi Yang2, Maohua Zhong2, Qinxue Hu3, Li Deng1, Huimin Yan1,2, 4*
1The Joint Laboratory for Translational Precision Medicine, a. Guangzhou Women and Children’s Medical Center, Guangzhou, 510623, China, and b. Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, Hubei, 430071, China; 2Mucosal Immunity Research Group, State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China; 3State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China. 4University of Chinese Academy of Sciences, Beijing 100049, China.

Running title: IgA inhibits MV evasion of type I IFN signaling
# These authors contributed equally to this work.
* Correspondence to: 
Huimin Yan, Mucosal Immunity Research Group, State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China. Tel and Fax: 86-27-87197103. E-mail: hmyan@wh.iov.cn (​mailto:hmyan@wh.iov.cn​)
NOTES
The authors declare no potential conflicts of interest.
ACKNOWLEDGEMENTS





Immunoglobulin A (IgA) can inhibit intracellular viral replication during its transporting across the epithelial cells. We find a monoclonal IgA antibody 7F1-IgA against N-terminal moiety of phosphoprotein (PNT) of measles virus (MV), which inhibits the intracellular replication of MV in Caco-2 cells but not in interferon-deficient Vero-pIgR cells. Transcytosis of 7F1-IgA across the MV-infected Caco-2 cells enhances the production of IFN-β and the expression of IFN-stimulated genes, rendering Caco-2 cells with higher anti-viral immunity. 7F1-IgA specifically interacts with MV P inside the MV-infected Caco-2 cell and prevents MV P from inhibiting the phosphorylation of JAK1 and STAT1. The intraepithelial interaction between 7F1-IgA and viral phosphoprotein results in an earlier and stronger phosphorylation of JAK1 and STAT1, and consequently a more efficient nuclear translocation of STAT1 for the activation of type I interferon pathway. Thus, IgA against phosphoprotein prevents a virus from evading type I IFN signaling and confers host epithelial cells efficient innate antiviral immunity, which potentiates a new antiviral target and an antiviral strategy.
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Immunoglobulin A (IgA) is the predominant antibody produced in mucosal areas and has a unique role in protection against viral infection of epithelia ADDIN EN.CITE 1-2. In addition to its immune exclusion activity to block viral attachment from apical surface of epithelial cells  ADDIN EN.CITE 3-4, IgA is able to exert intracellular antiviral function because the dimeric form of IgA (dIgA) can continuously transport through the lining epithelial cells mediated by the polymeric immunoglobulin receptor (pIgR)  ADDIN EN.CITE 5. Such capability renders IgA the opportunity to interact with viral targets inside an epithelial cell  ADDIN EN.CITE 6-7. Thus, IgA may interrupt the very early stages of viral replication intracellularly and interact directly with key viral components essential for the life cycle of a virus\o "Turula, 2018 #473". This further endows IgA with more potential anti-viral activities specific not only to viral surface components but also to more conserved viral non-surface and non-structural protein targets. In this regard, mucosal IgA may have a broader spectrum of antiviral activity than other isotypes of antibody
We previously demonstrated that IgA antibodies against H and F envelope antigens of measles virus (MV) are both potent in inhibition of viral replication through intracellular neutralization ADDIN EN.CITE 8. We also showed that an IgA antibody against matrix protein of MV can interact with newly synthesized matrix protein inside the epithelial cell during viral replication, indicating that IgA against viral internal target can indeed inhibit MV replication efficiently ADDIN EN.CITE 9. Such intracellular neutralization has also been confirmed for monoclonal IgA antibodies (mAbs) against different viral targets of several viruses including Sendai virus  ADDIN EN.CITE 10, influenza virus 11, and rotavirus 12. It is conceivable that, when IgA is transporting across the epithelial cells and exerts intracellular antiviral function, it has the opportunity to interact with viral targets during the replication of a virus. As viral phosphoprotein (P) plays essential roles in both viral transcription and replication, we further investigated the intracellular interaction between IgA antibody and viral phosphoprotein inside MV infected epithelial cells. We found that a monoclonal antibody 1D11-IgA targeting on the α-molecular recognition element (α-MoRE) of viral P blocks formation and function of P-N complex and thus inhibits viral RNA replication and mRNA expression ADDIN EN.CITE 13. However, another monoclonal antibody 7F1-IgA targeting on an different epitope of viral P does not show antiviral activity in the same Vero-pIgR cell system, although 7F1-IgA is able to transport through polarized cells and binds to P intracellularly with a similar efficiency as that of 1D11-IgA  ADDIN EN.CITE 13.





A Monoclonal 7F1-IgA Antibody Inhibits MV Replication in Caco-2 Cells but not in Vero-pIgR Cells
As reported previously  ADDIN EN.CITE 13, we found that 1D11-IgA, a monoclonal IgA antibody against MV phosphoprotein (P), inhibited intracellular MV replication efficiently in Vero-pIgR cells, whereas another monoclonal antibody 7F1-IgA against N-terminal moiety of P (PNT) specific on the region of 77aa to 86aa did not inhibit viral replication  ADDIN EN.CITE 13. Further test with serial concentrations of 7F1-IgA and 7F1-IgG antibodies, respectively, ranged from  2.5, 5, 10, 20 to 40 μg per transwell showed no intracellular neutralization activities against MV replication in Vero-pIgR cells (Figure 1A). However, when 7F1-IgA and 7F1-IgG antibodies were tested in the same two-chamber transwell system but seeded with Caco-2 cells instead of Vero-pIgR cells, 7F1-IgA showed significant activity to inhibit MV replication in a dose dependent manner while 7F1-IgG did not have such an effect (Figure 1B). Furthermore, 7F1–IgA showed higher inhibition activity than the 1D11-IgA at the same concentration (20μg/well) in MV-infected Caco-2 cells at an MOI of 0.4 or 1, although there was no significant difference at an MOI of 0.1 or 0.2 (Figure 1C). A significant different dynamics of MV replication in Caco-2 cells was observed when 7F1-IgA and 1D11-IgA were comparatively tested with control of irrelevant IgA or medium only at different time points post MV infection, in which 1D11-IgA and 7F1-IgA decreased viral replication by 36.5% and 54.8% at 72 h.p.i. respectively (Figure 1D). 
These data together indicate that 7F1-IgA inhibits MV intracellular replication in Caco-2 cells rather than Vero-pIgR cells, implying that the two monoclonal anti-P IgA antibodies have different activates and likely act through different mechanisms.

7F1-IgA Reinforces IFN-β Production and Related Responses in MV-infected Caco-2 Cells
Because of a homozygous deletion in chromosome 12 and the loss of type I interferon gene cluster  ADDIN EN.CITE 14, Vero cells are interferon-deficient,  and thus do not secrete interferon alpha or beta when infected by viruses 15. We asked whether the interferon-deficiency of Vero cells accounts for the difference in the intracellular antiviral activities of 1D11-IgA and 7F1-IgA in Vero-pIgR cells. Therefore, we detected IFN-β production in Vero-pIgR cells and Caco-2 cells infected by MV in the same transwell model. As expected, no detectable IFN-β was detected in Vero-pIgR cells treated with 7F1-IgA or an irrelevant IgA antibody (Figure 2A). In contrast, significant IFN-β production was detected in Caco-2 cells and the level of IFN-β production increased over time following MV infection (Figure 2A). It should be noted that much higher level of IFN-β was produced in cells treated with 7F1-IgA than that with medium alone or irrelevant IgA (Figure 2A). Correspondently, MV replication was much lower in cells treated with 7F1-IgA than that with medium alone or irrelevant IgA (Figure 1). These data suggested that 7F1-IgA was likely to be involved in up-regulating IFN-β signaling and production, which could lead to the inhibition of MV replication in Caco-2 cells.
We further investigated the expression of IFN-β and two IFN-stimulated genes in Caco-2 cells seeded in a transwell using quantitative-PCR (q-PCR). As shown in Figure 2B, the expression of IFN-β, ISG15 and PKR increased over time after MV infection. It should be noted that the expressions of all the three genes were significantly up-regulated following 7F1-IgA treatment compared to that in medium alone or treated with irrelevant IgA (Figure 2B).
Taken together, our data suggested that 7F1-IgA inhibits MV replication in Caco-2 cells likely mediated by up-regulating IFN-β signaling and production when infected by the virus.

7F1-IgA binds on MV P intracellularly and blocks the binding activity of MV P to both JAK1 and STAT1, so that More JAK1 and STAT1 can Be Phosphorylated in MV-infected Caco-2 Cells
It has been known that the PNT domain of measles virus phosphoprotein interacts with STAT1 to escape host interferon signaling  ADDIN EN.CITE 16-17.  Taking into account that the monoclonal 7F1-IgA, which bind to PNT domain on the region of 77aa to 86aa, reinforces the induction and production of interferon-β in MV-infected Caco-2 cells (Figure 2), we speculate that 7F1-IgA might specifically interact with newly synthesized phosphoprotein on PNT domain and interfere PNT domain to interact with STAT1 and some other interferon-induced proteins. To test this hypothesis, we firstly checked the pIgR expression of Caco-2 by immunofluorescence and confocal microscopy, which showed significant apical and basolateral expression of pIgR in polarized Caco-2 cell though with a little bit lower expression level than that in the Vero-pIgR cell (Supplemental Figure 1). Meanwhile, the 7F1-IgA antibody could be observed in Caco-2 cell and totally co-localized with pIgR (Supplemental Figure 1B), confirming efficient transcytosis of IgA through pIgR in polarized Caco-2 cell. Then, Caco-2 cells were grown in a transwell and infected with MV at an MOI of 1 and treated with 7F1-IgA or irrelevant IgA as control at 48 h.p.i, and then the cells were collected at 60 h.p.i. (i.e. 12 h after IgA treatment) for western blotting or immunoprecipitation (IP) assay at this time point for keeping the amount of MV P expressed at the same level between different groups (Figure 3A, B). The monoclonal antibody 7G4-IgG, which also binds on PNT domain but not at 7F1-IgA epitope (data not show), was used for the western blotting assay. As a result, PIRH2, MDA5, Tyk2, JAK1, p-JAK1, STAT1 and p-STAT1 could all be detected in MV-infected Caco-2 cell lysates as MV P. PIRH2, MDA5, Tyk2, JAK1 and STAT1 were all up-regulated in the MV infected cells compared to the uninfected (Figure 3A). It should be noted that similar expression levels of PIRH2, MDA5, Tyk2, JAK1 and STAT1 were detected whether treated with IgA or not. However, higher levels of phosphorylated JAK1 and STAT1 (p-JAK1, p-STAT1) were detected in the group treated with 7F1-IgA compared with the cells with irrelevant IgA or medium only (Figure 3A). This result suggested that 7F1-IgA transcytosis across the MV-infected cells enhanced the phosphorylation of JAK1 and STAT1.
To determine whether the enhanced phosphorylation of JAK1 and STAT1 by 7F1-IgA was mediated through transcytosis of 7F1-IgA or not, an experiment by competing 7F1-IgA with irrelevant IgA in different concentrations was performed. As similar as above described, Caco-2 cells were grown in a transwell and infected with MV at an MOI of 1 but treated with 7F1-IgA mixed with different amount of irrelevant IgA at 48 h.p.i, and then the cells were collected at 60 h.p.i. for western blotting. As shown in Figure 3B, MV P, IgA κ chain, STAT1, p-STAT1, JAK1 and p-JAK1 were detected with specific antibodies respectively. Compared with the treatment of 20 μg of 7F1-IgA (lane 2), the treatment with addition of 2 μg irrelevant IgA together with 20 μg of 7F1-IgA had no significant effect on the levels of p-STAT1 and p-JAK (lane 4). However, the treatment with addition of 20 μg irrelevant IgA together with 20 μg of 7F1-IgA reduced the level of p-STAT1 significantly and the level of p-JAK1 slightly (lane 5), while total STAT1 and JAK1 expression remained unchanged. This suggested a competition between irrelevant IgA and 7F1-IgA during transcytosis, i.e. the addition of irrelevant IgA might compete pIgR and interfere the transcytosis of 7F1-IgA, thus alleviate the rescue of p-STAT1 level by 7F1-IgA. In another word, the observed enhancement of phosphorylation of JAK1 and STAT1 by 7F1-IgA was mediated through transcytosis. 
We further performed immunoprecipitation test with the same cell lysates as above using a monoclonal IgG antibody (8C4-IgG) against different epitope of MV P from that of 7F1-IgA but also bind to PNT domain. As shown in Figure 3B, MDA5, STAT1 and JAK1, but neither PIRH2, Tyk2, p-JAK1 nor p-STAT1 could be detected in the MV P immunoprecipitated complex. It should be noted that IgA κchain could be detected in the immunoprecipitated complex when the Caco-2 cells treated with 7F1-IgA, indicating that 7F1-IgA interacted specifically with PNT domain in the immunoprecipitated complex. In contrast, similar amount of MDA5 but significant fewer amounts of JAK1 and STAT1 could be detected in 7F1-IgA involved complex compared to the cells treated with irrelevant IgA or medium only. This data confirmed that MV P can interact directly with MDA5, JAK1 and STAT1, but not with PIRH2 or Tyk2. More importantly, the data further suggested that 7F1-IgA which binds to PNT domain can encumber MV P to interact with both JAK1 and STAT1. Interestingly, no p-STAT1 or p-JAK1 could be detected in this MV P precipitated complex, suggesting that both JAK1 and STAT1 bound by PNT domain are hardly to be phosphorylated, or PNT domain cannot bind to p-STAT1 and p-JAK1.
Taken together, the data demonstrated that 7F1-IgA, which binds on PNT domain of MV P intracellularly, can block the binding activity of MV P to both JAK1 and STAT1 in MV-infected Caco-2 cells during transcytosis (Figure 3B), so that JAK1 and STAT1 are protected from binding by PNT domain and thus more STAT1 and JAK1 can be phosphorylated in MV-infected Caco-2 cells (Figure 3A).

7F1-IgA Confers MV-infected Caco-2 Cells Earlier and Higher Phosphorylation of JAK1 and STAT1
To get more insight into how 7F1-IgA participates in the JAK1/STAT1 signaling and helps cell to keep higher phosphorylation of JAK1 and STAT1, we further observed the dynamic profiles of JAK1, p-JAK1, STAT1, and p-STAT1 in MV-infected Caco-2 cells when treated with 7F1-IgA or not. With MV-infected Caco-2 cells grown in the same transwell model used as above, no MV P could be detected in the Caco-2 cells at the time point of initial inoculation of MV (-2 h.p.i, Figure 4). Detectable MV P could be observed in Caco-2 cells after 2 h attachment of MV on the Caco-2 cells (0 h.p.i, Figure 4), but not after attachment of MV at the time points of 12 and 24 h.p.i. (Figure 4). The dynamics of MV P expressions were detected by western blotting and shown in the first row of right panel in Figure 4, in which the MV P expressed similarly in the group treated with 7F1-IgA and medium only, but a little bit higher in the group treated with irrelevant IgA (Figure 4, MV P). In parallel, constitutive expressions of JAK1 and STAT1 could be observed at all detected time points post MV-infection (Figure 4). The amounts of JAK1 and STAT1 did not change significantly at different time points (0, 12, 24, 36, 48, 60, 72 h.p.i.) post MV infection (Figure 4, JAK1 and STAT1 panel). Similar expression profiles of JAK1 and STAT1 were observed whether treated with 7F1-IgA or not, which suggested that the engagement of IgA antibody did not change the expression of JAK1 and STAT1 in the MV-infected cells. In contrast, phosphorylated JAK1 and STAT1 (p-JAK1 and p-STAT1) were changed at different time points after MV infection and treatment with 7F1-IgA (Figure 4, p-JAK1, p-STAT1 panel). As similar as MV P,  p-JAK1 and p-STAT1 could be observed after attachment of MV at the time point of 0 h.p.i compared with the cells before MV inoculation on the Caco-2 cells (-2 h.p.i), but could not detected until at least 24 h.p.i. 
    These data showed the initiation of MV-infection and the first phosphorylation round of JAK1 and STAT1 indicated by detectable p-JAK1 and p-STAT1 at 0 h.p.i.. Interestingly, significant p-JAK1 could be observed earlier (36 h.p.i) when the MV-infected Caco-2 cells were treated with 7F1-IgA than those cells treated with irrelevant IgA or medium alone (48 h.p.i). Meanwhile, much higher p-JAK1 could be observed at 48 and 60 h.p.i in 7F1-IgA treated cells compared with the cells treated with irrelevant IgA or medium only (Figure 4, p-JAK1, panel).  Similarly, more than five times higher amount of p-STAT1 could be detected in 7F1-IgA treated cells at earlier time point (36 h.p.i) compared with the cells treated with irrelevant IgA or medium only (48 h.p.i) (Figure 4, p-STAT1 panel). The data suggested that 7F1-IgA confers MV-infected Caco-2 cells earlier and more potent phosphorylation of JAK1 and STAT1, which might endow Caco-2 cells with earlier and higher innate anti-viral responses.

7F1-IgA Protects STAT1 from Binding by MV P and Facilitates Nuclear Translocation of STAT1 in MV-infected Caco-2 Cells
It has been well known that once activated by initial viral infection induced IFN, JAK1 phosphorylates IFN receptor chains, leading to the recruiting  of STAT1  ADDIN EN.CITE 18, and the following phosphorylation of STAT1 19. The p-STAT1 then releases from the IFN receptor and exposes a nuclear localization signal that facilitates nuclear translocation. Once in the nucleus, p-STAT1 serves as an essential component in the IFN-stimulated response element (ISRE) that transcriptionally drives ISG expression 20. To investigate whether 7F1-IgA participates in the process of nuclear translocation of STAT1,  we further observed distribution and translocation of STAT1 and MV P when the MV-infected Caco-2 cells treated with 7F1-IgA, irrelevant IgA or medium only by using immunofluorescence and confocal microscopy. The monoclonal antibody used for  immunofluorescence staining of P was 7G4-IgG, which binds on different epitope from 7F1-IgA. Again in the same transwell model,  constitutive expression  of STAT1 could be observed exclusively in cytoplasm of Caco-2 cells (Figure 5A, upper panel). The STAT1 was then located in nuclei when stimulated by IFN-β (Figure 5A, lower panel). When Caco-2 cells were infected by MV, STAT1 mostly remained in the cytoplasm, which was highly colocalized with MV P around the nuclei (Figure 5B, panel of Medium). However, when the MV-infected caco-2 cells were treated with 7F1-IgA, prominent higher level of STAT1 could be observed in nuclei (Figure 5B, panel of 7F1-IgA) compared to that treated with irrelevant IgA (Figure 5B, panel of Irrelevant IgA) or medium only (Figure 5B, panel of Medium), though certain amount of P was also observed in cytoplasm and colocalized with some STAT1 (Figure 5B, panel of 7F1-IgA). The data showed that MV P binds with STAT1 tightly in the cytoplasm and blocks phosphorylation and nuclear translocation of STAT1. In term of the cell, the results suggested that 7F1-IgA protects STAT1 from binding by MV P and facilitates nuclear translocation of STAT1 in MV-infected Caco-2 cells.

Binding of 7F1-IgA on MV P Prevents JAK1 and STAT1 from Binding by MV P and Recovers Efficient Phosphorylation of JAK1 and STAT1 in Reconstituted 293T Cells
Having observed that 7F1-IgA confers MV-infected Caco-2 cells earlier and higher phosphorylation of JAK1 and STAT1, and thus further facilitates nuclear translocation of STAT1, we sought to further determine how IgA participates into the interaction among MV P, JAK1, and STAT1. For more clear investigation on the involvement of MV P in the interactions, expression plasmids encoding Flag- or HA-tagged full length MV P, JAK1, STAT1 were constructed and evaluated for their interactions by co-transfection into 293T cells and co-IP assay with or without 7F1-IgA.  Besides the anti-HA or anti-Flag antibody were used, the monoclonal anti-P 7G4-IgG, anti-JAK1, anti-STAT1 were also used in parallel for detection of P, JAK1 and STAT1 respectively in western blotting assay.
Firstly, when Flag-MV P, HA-JAK1, and IgA (Figure 6A left panel), or Flag-MV P, HA-STAT1 and IgA (Figure 6A right panel) were co-transfected into 293T cells and immunoprecipitated by anti-Flag beads, both MV P and JAK1 or MV P and STAT1 could be detected in the complex, which further demonstrated that MV P binds prominently with both JAK1 and STAT1 in this reconstituted 293T cells (Figure 6A).  It should be noted that much less JAK1 or STAT1 but prominent IgA antibody including heavy and light chain instead could be detected in the complex when 7F1-IgA engaged in the system compared to that of medium only or irrelevant IgA (Figure 6A). This revealed that 7F1-IgA impairs binding ability of P onto JAK1 and STAT1 by binding competition.
Secondly, when Flag-JAK1, HA-MV P,  and IgA (Figure 6B left panel), or Flag-STAT1, HA-MV P and IgA (Figure 6B right panel) were co-transfected into 293T cells and immunoprecipitated by anti-Flag beads, both MV P and JAK1 or MV P and STAT1 could also be detected in the complex,  which demonstrated again that MV P binds prominently with both JAK1 and STAT1 no matter what tag is attached  (Figure 6B). It should be noted again that much less MV P could be detected in the immunoprecipitated complex when 7F1-IgA engaged in the system compared to that of medium only or irrelevant IgA (Figure 6B). Furthermore, no IgA could be detected by either IgA H or L chain in the immunoprecipitated complex (Figure 6B) indicating that only MV P free from binding by 7F1-IgA may bind to JAK1 or STAT1. It is sugguested that MV P can not bind to JAK1 or STAT1 once it is bound by 7F1-IgA, i.e. MV P is blocked by 7F1-IgA to bind to JAK1 and STAT1. The data also suggested that 7F1-IgA cannot bind to MV P once P is bound on JAK1 or STAT1 in advance. Taken together, the data demonstrated that 7F1-IgA directly intervenes the interaction between MV P and JAK1 or STAT1 by competitive binding.
Lastly, when Flag-JAK1 was transfected into 293T cells with IFN-β stimulation and subjected to immunoprecipitation by anti-Flag beads, p-JAK1 in immunoprecipitated complex and endogenous p-STAT1 could be detected (Figure 6C,  the first column). When HA-MV P was co-transfected together with Flag-JAK1, significant less p-JAK1 and endogenous p-STAT1 could be detected (Figure 6C, the second column), indicating that HA-MV P inhibited phosphorylation of both JAK1 and STAT1 in this reconstituted in-vitro system. However, when 7F1-IgA was co-transfected together with both HA-MV P and Flag-JAK1 (Figure 6C, the third column), almost the same amount of p-JAK1 in the immunoprecipitated complex and endogenous p-STAT1 could be detected as that of no MV P involved (Figure 6C, the first column). This demontrated again that MV P can inhibit phosphorylation of JAK1 and STAT1 even in this reconstituted system and that the MV P-inhibited phosphorylation of JAK1 and STAT1 can be counteracted by 7F1-IgA within the cell.





In the present study, we functionally characterized a monoclonal antibody 7F1-IgA targetingon N-terminal moiety of MV P for its intracellular antiviral activity, and analyzed the intracellular binding and interactions among 7F1-IgA, MV P and the key molecules JAK1 and STAT1 of the IFN-β signaling pathway in polarized Caco-2 cell cultured in  a two-chamber transwell system.  We demonstrated that 7F1-IgA specifically interacts with PNT domain and prevents MV P from inhibiting the phosphorylation of both JAK1 and STAT1. The study reveals that IgA against phosphoprotein has a potential role in viral infected epithelial cell to prevent a virus from evading IFN-β signaling and thus confers host epithelial cells more efficient innate antiviral immunity. With this specific activity, IgA can actively play role in the early intraepithelial antiviral activities by protecting the IFN-β signaling from antagonism by a virus. Thus, the IgA in effect confers enhanced intracellular antiviral immunity in mucosal epithelial cells at early viral life cycle when epithelial cell gets infected by a virus. This allows antibody to control viral replication cycle itself rather than to bind to viral particle for neutralizing viral particle infectivity, which should be much more effective to keep virus at bay.
Viral infection usually assaults upon the mucosal cells inevitably induce antiviral responses and following dynamic warfare between the virus and cells ADDIN EN.CITE 22. The host cell has innate immunity, in particular the IFN signaling, to sense and protect against MV infection, while MV has evolved multiple mechanisms to antagonize the early induction of IFN and following activation of  IFN pathway.  Our data show that 7F1-IgA does inhibit MV intracellular replication in IFN-producing cell line effectively,  but it does not work in cell line having a defect in IFN production. This strongly suggests that 7F1-IgA should exert intracellular antiviral function by mechanism related with IFN production. Taking into account that the binding site for 7F1-IgA is located at aa77-aa86 (RIRGQGPGES) in N-terminal moiety of phosphoprotein (PNT) ADDIN EN.CITE 13. These results indicate that the domain containing the epitope of 7F1-IgA in phosphoprotein is a functional domain to suppress cellular induction of IFN.
 It is well- known that the MV P gene codes for three proteins: P,  V,  and C via an RNA editing process and an alternative reading frame.  V protein shares the first 231 amino acids (i.e  PNT) with P and in addition has a 68 carboxyl-terminal highly conserved amino acids translated from a different ORF accessed by the cotranscriptional insertion of a pseudo-templated G residue ADDIN EN.CITE 27-28HYPERLINK \l "_ENREF_25" \o "Devaux, 2004 #378". Therefore, it is predictable that V should contain the same epitope of the aa77-aa86 as phosphoprotein and be recognized also by 7F1-IgA. Our data shows that 7F1-IgA can bind to over expressed P and V proteins in 293T cell assayed by Western blotting (data not shown). This suggests that 7F1-IgA possibly can also interact with V protein inside MV infected cells though it is not confirmed further due to lack of V specific antibody for detection. Since PNT is present in both P and V proteins, and has same biological function in these two proteins, it is likely that 7F1-IgA exerts its intracellular antiviral function mediated also by binding V because the V is intensively demonstrated as a viral virulent factor which is active in interfering with the host IFN response ADDIN EN.CITE 29-35. However, the contributive percentage of PNT derived from P and V during infection and the potential function of P, V, and C warrant further investigations.
Our present data showed that 7F1-IgA can bind to phosphoprotein efficiently and significantly neutralize P to interact with JAK1 and STAT1 because P can be detected in the Co-IP complex (Figure 3B) and also in the reconstituted 293T cell system with only full length P gene transfected (Figure 6). This confirms that P can bind and block phosphorylation of STAT1 which is in line with previous studies on functions of MV phosphoprotein ADDIN EN.CITE 36-37. This also suggests that P can bind the JAK1 as well (Figure 6A), which is only demonstrated for V previously ADDIN EN.CITE 34 . Therefore, we reveal that 7F1-IgA can actually counteract the blocking effects of MV phosphoprotein on both JAK1 and STAT1 phosphorylation. From the virus side, this suggest that the MV P plays dual roles as both a co-factor of RdRp and an inhibitor  of the IFN-induced JAK/STAT signaling pathway.
 Technically, our approach suggests that viral-specific IgA antibodies might a good tools or at least a good complement for exploring virological functions of viral proteins in its native and functional status during viral infection. For example, it is well demonstrated by biochemistry analysis that the tyrosine 110 in the amino-terminal domain of MV phosphoprotein (PNT) is required to block STAT1 phosphorylation ADDIN EN.CITE 36. Here in our study, it might be speculated that the functional domain for P to block STAT1 phosphorylation also involves aa77-aa86 residues besides tyrosine 110, because the level of STAT1 phosphorylation sustains when 7F1-IgA applied to the MV infected cells. As the site    of aa77- aa86  is relatively close to Y110 which is a key for  MV P to bind  with  STAT1, the 7F1-IgA may hinder the binding of MV P and STAT1 through effect of steric hindrance. However, according to a published 3D model, it is hardly possible that binding of the 7F1-IgA with P on aa77- aa86  an cause effect of steric hindrance on Y110.On the other hand, the functional domain for P as an indispensable polymerase cofactor for synthesis of viral genome RNA and mRNA is not interfered by 7F1-IgA because 7F1-IgA does not inhibit viral replication in cell line having a defect in IFN production though it can bind to PNT domain efficiently inside cells. It is suggested that aa77-aa86 residues along with tyrosine 110 are not in functional domain of P as viral polymerase cofactor. For another example, MDA5 can be detected in the P-JAK1-STAT1 complex (Figure 3B), which may include some V protein catched by 8C4-IgG, since 8C4-IgG specific to PNT of phosphoprotein may interact with both phosphoproteinand V proteins. This result suggested V of MV can also interact with MDA5 as reported in other paramyxoviruses such as simian virus 5, human parainfluenza virus 2, mumps virus, Sendai virus, Hendra virus, this interaction may mediated by Zn-bingding domain on V protein.
More importantly, our results reveal that IgA antibodies against viral non-surface or non-structural components are able to intervene in any viral replication stage that can help cell mount a more effective multifaceted response to virus infection in an attempt to inhibit viral gene expression, clear viral debris and recover to healthy state. However, this usually can be achieved effectively when the IgA antibodies are ready in advance before viral infection. In this regard, mucosal vaccines designed for induction of specific IgA against viral components critical for viral replication should be more effective for protection against viral infection. As the viral non- surface and non- structural protein genes are usually more conserved than the surface proteins, this mucosal vaccine strategy may provide broaden antiviral spectrum with cross reaction against related viruses among viral strains or even among viral species ADDIN EN.CITE 39-40
By itself, IgA antibody against viral non-surface or non-structural protein may also be effective antiviral drug for prophylactic as well as therapeutic treatment. With development of monoclonal antibody techniques, we may make IgA antibodies against more viral components which cannot be induced by natural infection or even mucosal vaccines. Thus, there will be battles won much more by cell side to stop viral invasion and replication than by viral side when the virus attempts to control the cell. More essentially, IgA antibody possesses natural activity to transport through epithelial cells which makes IgA unique intracellular antiviral drug may without side-effect to cells. In a word, this study not only provides insight into a unique antiviral mechanism of IgA antibody, but also reveals important functional domain of P and suggests P is a valuable anti-viral target for potential drug screening.
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rabbit anti p-Jak1 	Cell Signaling Technology	Cat#3331
rabbit anti-STAT1 	Abcam	Cat#109320
rabbit anti p-Stat1 	Cell Signaling Technology	Cat#7649
rabbit anti Pirh2 	Abcam	Cat#ab189247
rabbit anti Tyk2 	Abgent	Cat#AW5349
rabbit anti MDA5	Abcam	Cat#126630
goat anti mouse kappa-HRP	Southern Biotech	Cat#1050-05
goat anti mouse IgA-HRP	Southern Biotech	Cat#1040-05
mouse anti Flag 	Sigma-Aldrich	Cat#A2220
mouse anti HA 	Covance	Cat#901501
mouse anti MV P 		Clone No.:7G4-IgG
mouse anti MV P		Clone No,:8C4-IgG
mouse anti β-actin	Beijing Ray Antibody Biotech	Cat#RM2001
goat anti mouse IgG-HRP	Jackson	Cat#115-035-164
goat anti rabbit IgG-HRP	Jackson	Cat#115-035-008
Alexa Fluor®488 goat-anti-mouse IgG 	Invitrogen	Cat#CA11001S
Alexa Fluor® 555 goat-anti-rabbit IgG	Invitrogen	Cat#A21422

Cells, Viruses, and Animals
Caco-2 (ATCC HTB-37), Vero C1008 (ATCC CRL-1587), human HEK-293T (ATCC CRL-3216) cell lines were all obtained from ATCC. Vero-pIgR cells constitutively expressing pIgR was generated based on the Vero cell line. The measles virus (MV) Edmonston strain (ATCC VR-24) was obtained from ATCC and propagated in Vero cells.
Female BALB/c mice, 6-8 weeks old, were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd and maintained under specific pathogen-free (SPF) conditions in Experimental Animal Center of Wuhan Institute of Virology, Chinese Academy of Sciences (WIV, CAS). All animal experiments were approved by the Animal Welfare and Ethical Review Committee of WIV, and performed according to Regulations for the Administration of Affairs Concerning Experimental Animals, China.
METHODS
Production of Monoclonal IgG and IgA antibodies
Monoclonal antibodies were generated as previously described  ADDIN EN.CITE \o "Zhou, 2011 #115", \o "Zhou, 2018 #429"in accordance with the Animal Welfare and Ethical Review Committee of WIV. Briefly, four IgG antibodies (1D11-IgG, 7F1-IgG, 7G4-IgG, and 8C4-IgG) were obtained by the conventional hybridoma technique  ADDIN EN.CITE \o "Zhou, 2011 #115", \o "Kohler, 1975 #161" with phosphoprotein of measles virus Edmonston strain (GenBank accession no of P gene: AAF85692.1). Two IgA antibodies 1D11-IgA and 7F1-IgA were obtained by repeated cycles of limiting dilution and spontaneous isotype switching from IgG antibodies 1D11-IgG and 7F1-IgG, respectively. One IgA monoclonal antibody against HIV gp120 protein was used as irrelevant IgA isotype control (a gift from Y. T. Huang at Case Western Reserve University, OH). Large scale of monoclonal antibody production was performed by the preparation of mouse ascites  ADDIN EN.CITE 9.
Intracellular Virus Neutralization Assay 
About 1*105 cells of Vero-pIgR or Caco-2 cell seeded and cultured in 0.4-μm-pore-size Transwells (Costar, REF3460) for 4 days, or 7 days alternatively for forming polarized cell monolayer. The monolayer cells were infected with MV at an MOI of 1 or indicated MOI for two hours and washed by fresh medium for three times. Then, 20 μg or serial concentrations of mAb in 120 μl medium was added into the basal chambers with medium alone being used as the negative control. Cell lysates were collected at 48 h in Vero-pIgR cells or 72 h in Caco-2 cells after initial exposure to the virus. Virus titers were quantified by a plaque assay as described previously  ADDIN EN.CITE \o "Yan, 2002 #458", \o "Hsiung, 1958 #411".
ELISA and q-PCR Assay
IFN-β in supernatant was assessed by IFN-β ELISA kit (PBL Assay Science). Total RNA of cells was prepared by Trizol extraction and then converted into cDNA. Quantitative (q)-PCR was performed by using the cDNAs as templates under a CFX Connect Real-Time System (Bio-Rad). The primers used for q-PCR were IFN-β (Forward: 5'-GCTTGGATTCCTACAAAGAAG-3', Reverse: 5'-ATAGATGGTCAATGCGGCG-3'); ISG15 (Forward: 5'-TGGACAAATGCGACGAACC-3', Reverse: 5'-TCAGCCGTACCTCGTAGG-3'); PKR (Forward: 5’-GCCGCTAAACTTGCATATCTT-3’, Reverse: 5’-TCACACGTAGTAGCAAAAGAA-3’) and GAPDH (Forward: 5’-GACAAGCTTCCCGTTCTCAG-3’, Reverse: 5’-GAGTCAACGGATTTGGTCGT-3’). The mRNA levels were normalized against those of GAPDH and the delta-delta CT values were calculated and presented over uninfected cell control.
Immunofluorescent Staining and Confocal Microscopy
Cells were fixed by the fixed buffer (4% paraformaldehyde, and 0.1% Triton X-100 in PBS). Anti-P 7G4-IgG mAb was used to recognize MV phosphoprotein, and Alexa Fluor®488 goat-anti-mouse IgG  was used as the secondary antibody. Anti-STAT1 antibody was used to recognize STAT1 protein in cells, with Alexa Fluor® 555 goat-anti-rabbit IgG being used as the secondary antibody. DAPI was used to dye the nuclei of cells.
Co-immunoprecipitation (Co-IP) in Caco-2 Cell
Collected cells were treated by cell lysis buffer (1% Triton X-100 and 0.2% protease inhibitor in TBS). The cell lysates were then subjected to anti-MV P immunoprecipitation using beads bound with the anti-P 8C4-IgG antibody. Immunoprecipitation was prepared in 4℃ overnight. Following three washes with the cell lysis buffer, the immunoprecipitates were eluted from beads by 0.1 M Gly-HCl (pH 3.5). Cell lysates and immunoprecipitates were assessed by western blotting.
Immunoprecipitation in 293T Cell
Flag-MV P, HA-MV P, Flag-JAK1, Flag-STAT1, HA-JAK1, HA-STAT1, 7F1-IgA H chain, 7F1-IgA Κchain, irrelevant IgA H chain, and irrelevant IgA Κ chain were respectively cloned on pFB-Dual-CMV-EF1α plasmid (Supplemental Figure 1). About 2*105 293T cells were seeded into 6-well plate for 12 h before transfection, and then 1.5 μg of each plasmids were transfected into 293T cell with DOTAP (Invitrogen). 1000 U/ml of recombinant IFN-β was added at 24 h after transfection if needed. At 36 h after transfection, cells were collected and treated with cell lysis buffer (1% triton X-100 and 0.2% protease inhibitor in TBS). Anti-Flag beads (Invitrogen) used for immunoprecipitated complex. Immunoprecipitation was prepared in 4℃ overnight. Then the beads were washed three times with the cell lysis buffer and the immunoprecipitates were eluted from beads by PH=3.5 0.1M Gly-HCl. The cell and the immunoprecipitates sample were assessed by western blotting.
Statistical analysis




1.	Lamm, M. E., Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol 1997, 51, 311-340. DOI: DOI 10.1146/annurev.micro.51.1.311.2.	Brandtzaeg, P., Secretory IgA: Designed for Anti-Microbial Defense. Frontiers in immunology 2013, 4, 222. DOI: 10.3389/fimmu.2013.00222.3.	Corthesy, B., Multi-faceted functions of secretory IgA at mucosal surfaces. Frontiers in immunology 2013, 4. DOI: Artn 18510.3389/Fimmu.2013.00185.4.	Pabst, O., New concepts in the generation and functions of IgA. Nature reviews. Immunology 2012, 12 (12), 821-32. DOI: 10.1038/nri3322.5.	Kaetzel, C. S.; Robinson, J. K.; Chintalacharuvu, K. R.; Vaerman, J. P.; Lamm, M. E., The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proceedings of the National Academy of Sciences of the United States of America 1991, 88 (19), 8796-800.6.	Horton, R. E.; Vidarsson, G., Antibodies and their receptors: different potential roles mucosal defense. Frontiers in immunology 2013, 4. DOI: Unsp 20010.3389/Fimmu.2013.00200.7.	Turula, H.; Wobus, C. E., The Role of the Polymeric Immunoglobulin Receptor and Secretory Immunoglobulins during Mucosal Infection and Immunity. Viruses 2018, 10 (5). DOI: 10.3390/v10050237.8.	Yan, H. M.; Lamm, M. E.; Bjorling, E.; Huang, Y. T., Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model. Journal of virology 2002, 76 (21), 10972-10979. DOI: 10.1128/Jvi.76.21.10972-10979.2002.9.	Zhou, D. H.; Zhang, Y.; Li, Q. L.; Chen, Y. Q.; He, B. X.; Yang, J. Y.; Tu, H. B.; Lei, L.; Yan, H. M., Matrix Protein-Specific IgA Antibody Inhibits Measles Virus Replication by Intracellular Neutralization. Journal of virology 2011, 85 (21), 11090-11097. DOI: 10.1128/Jvi.00768-11.10.	Mazanec, M. B.; Kaetzel, C. S.; Lamm, M. E.; Fletcher, D.; Nedrud, J. G., Intracellular neutralization of virus by immunoglobulin A antibodies. Proceedings of the National Academy of Sciences of the United States of America 1992, 89 (15), 6901-5.11.	Mazanec, M. B.; Nedrud, J. G.; Kaetzel, C. S.; Lamm, M. E., A three-tiered view of the role of IgA in mucosal defense. Immunology today 1993, 14 (9), 430-5. DOI: 10.1016/0167-5699(93)90245-G.12.	Burns, J. W.; SiadatPajouh, M.; Krishnaney, A. A.; Greenberg, H. B., Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996, 272 (5258), 104-107. DOI: DOI 10.1126/science.272.5258.104.13.	Zhou, D. H.; Yang, Y.; Zhao, B. L.; Yu, J.; Cao, Y.; Yan, H.; Zhao, W.; Chen, L. Y.; Chen, F.; Li, X. D.; Zhang, E. J.; Yang, J. Y.; Zhong, M. H.; Chen, M. Z.; Hu, Q. X.; Deng, L.; Yan, H. M., IgA targeting on the alpha-molecular recognition element (alpha-MoRE) of viral phosphoprotein inhibits measles virus replication by interrupting formation and function of P-N complex intracellularly. Antiviral research 2018, 161, 144-153. DOI: 10.1016/j.antiviral.2018.11.014.14.	Osada, N.; Kohara, A.; Yamaji, T.; Hirayama, N.; Kasai, F.; Sekizuka, T.; Kuroda, M.; Hanada, K., The genome landscape of the african green monkey kidney-derived vero cell line. DNA research : an international journal for rapid publication of reports on genes and genomes 2014, 21 (6), 673-83. DOI: 10.1093/dnares/dsu029.15.	Desmyter, J.; Melnick, J. L.; Rawls, W. E., Defectiveness of Interferon Production and of Rubella Virus Interference in a Line of African Green Monkey Kidney Cells (Vero). J Virol 1968, 2 (10), 955-&.16.	Devaux, P.; Priniski, L.; Cattaneo, R., The measles virus phosphoprotein interacts with the linker domain of STAT1. Virology 2013, 444 (1-2), 250-6. DOI: 10.1016/j.virol.2013.06.019.17.	Devaux, P.; Hudacek, A. W.; Hodge, G.; Reyes-Del Valle, J.; McChesney, M. B.; Cattaneo, R., A recombinant measles virus unable to antagonize STAT1 function cannot control inflammation and is attenuated in rhesus monkeys. Journal of virology 2011, 85 (1), 348-56. DOI: 10.1128/JVI.00802-10.18.	Heim, M. H.; Kerr, I. M.; Stark, G. R.; Darnell, J. E., Jr., Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 1995, 267 (5202), 1347-9.19.	Fleming, S. B., Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists. Vaccines 2016, 4 (3). DOI: 10.3390/vaccines4030023.20.	Schneider, W. M.; Chevillotte, M. D.; Rice, C. M., Interferon-stimulated genes: a complex web of host defenses. Annual review of immunology 2014, 32, 513-45. DOI: 10.1146/annurev-immunol-032713-120231.21.	Leung, D. W., Mechanisms of Non-segmented Negative Sense RNA Viral Antagonism of Host RIG-I-Like Receptors. Journal of molecular biology 2019. DOI: 10.1016/j.jmb.2019.06.002.22.	Kretschmer, S.; Lee-Kirsch, M. A., Type I interferon-mediated autoinflammation and autoimmunity. Current opinion in immunology 2017, 49, 96-102. DOI: 10.1016/j.coi.2017.09.003.23.	Shaffer, J. A.; Bellini, W. J.; Rota, P. A., The C protein of measles virus inhibits the type I interferon response. Virology 2003, 315 (2), 389-97.24.	Chinnakannan, S. K.; Nanda, S. K.; Baron, M. D., Morbillivirus v proteins exhibit multiple mechanisms to block type 1 and type 2 interferon signalling pathways. PloS one 2013, 8 (2), e57063. DOI: 10.1371/journal.pone.0057063.25.	Andrejeva, J.; Childs, K. S.; Young, D. F.; Carlos, T. S.; Stock, N.; Goodbourn, S.; Randall, R. E., The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proceedings of the National Academy of Sciences of the United States of America 2004, 101 (49), 17264-9. DOI: 10.1073/pnas.0407639101.26.	Cui, S.; Eisenacher, K.; Kirchhofer, A.; Brzozka, K.; Lammens, A.; Lammens, K.; Fujita, T.; Conzelmann, K. K.; Krug, A.; Hopfner, K. P., The C-terminal regulatory domain is the RNA 5 '-triphosphate sensor of RIG-I. Mol Cell 2008, 29 (2), 169-179. DOI: 10.1016/j.molcel.2007.10.032.27.	Bellini, W. J.; Englund, G.; Rozenblatt, S.; Arnheiter, H.; Richardson, C. D., Measles virus P gene codes for two proteins. Journal of virology 1985, 53 (3), 908-19.28.	Devaux, P.; Cattaneo, R., Measles virus phosphoprotein gene products: conformational flexibility of the P/V protein amino-terminal domain and C protein infectivity factor function. Journal of virology 2004, 78 (21), 11632-40. DOI: 10.1128/JVI.78.21.11632-11640.2004.29.	Takeuchi, K.; Kadota, S. I.; Takeda, M.; Miyajima, N.; Nagata, K., Measles virus V protein blocks interferon (IFN)-alpha/beta but not IFN-gamma signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Lett 2003, 545 (2-3), 177-82.30.	Yokota, S.; Saito, H.; Kubota, T.; Yokosawa, N.; Amano, K.; Fujii, N., Measles virus suppresses interferon-alpha signaling pathway: suppression of Jak1 phosphorylation and association of viral accessory proteins, C and V, with interferon-alpha receptor complex. Virology 2003, 306 (1), 135-46.31.	Caignard, G.; Bourai, M.; Jacob, Y.; Infection, M. p. I. M. A. P.; Tangy, F.; Vidalain, P. O., Inhibition of IFN-alpha/beta signaling by two discrete peptides within measles virus V protein that specifically bind STAT1 and STAT2. Virology 2009, 383 (1), 112-20. DOI: 10.1016/j.virol.2008.10.014.32.	Ramachandran, A.; Parisien, J. P.; Horvath, C. M., STAT2 is a primary target for measles virus V protein-mediated alpha/beta interferon signaling inhibition. Journal of virology 2008, 82 (17), 8330-8. DOI: 10.1128/JVI.00831-08.33.	Palosaari, H.; Parisien, J. P.; Rodriguez, J. J.; Ulane, C. M.; Horvath, C. M., STAT protein interference and suppression of cytokine signal transduction by measles virus V protein. Journal of virology 2003, 77 (13), 7635-44.34.	Ohno, S.; Ono, N.; Takeda, M.; Takeuchi, K.; Yanagi, Y., Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction. The Journal of general virology 2004, 85 (Pt 10), 2991-9. DOI: 10.1099/vir.0.80308-0.35.	Childs, K.; Randall, R.; Goodbourn, S., Paramyxovirus V Proteins Interact with the RNA Helicase LGP2 To Inhibit RIG-I-Dependent Interferon Induction. Journal of virology 2012, 86 (7), 3411-3421. DOI: 10.1128/Jvi.06405-11.36.	Devaux, P.; von Messling, V.; Songsungthong, W.; Springfeld, C.; Cattaneo, R., Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology 2007, 360 (1), 72-83. DOI: 10.1016/j.virol.2006.09.049.37.	Caignard, G.; Guerbois, M.; Labernardiere, J. L.; Jacob, Y.; Jones, L. M.; Infectious Mapping Project, I. M.; Wild, F.; Tangy, F.; Vidalain, P. O., Measles virus V protein blocks Jak1-mediated phosphorylation of STAT1 to escape IFN-alpha/beta signaling. Virology 2007, 368 (2), 351-62. DOI: 10.1016/j.virol.2007.06.037.38.	Desfosses, A.; Milles, S.; Jensen, M. R.; Guseva, S.; Colletier, J. P.; Maurin, D.; Schoehn, G.; Gutsche, I.; Ruigrok, R. W. H.; Blackledge, M., Assembly and cryo-EM structures of RNA-specific measles virus nucleocapsids provide mechanistic insight into paramyxoviral replication. Proceedings of the National Academy of Sciences of the United States of America 2019. DOI: 10.1073/pnas.1816417116.39.	Calzas, C.; Chevalier, C., Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections. Frontiers in immunology 2019, 10, 1605. DOI: 10.3389/fimmu.2019.01605.40.	Pattyn, J.; Van Keer, S.; Tjalma, W.; Matheeussen, V.; Van Damme, P.; Vorsters, A., Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature. Papillomavirus research 2019, 8, 100185. DOI: 10.1016/j.pvr.2019.100185.41.	Kohler, G.; Milstein, C., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256 (5517), 495-7.42.	Hsiung, G. D.; Mannini, A.; Melnick, J. L., Plaque assay of measles virus on Erythrocebus patas monkey kidney monolayers. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine 1958, 98 (1), 68-70.
2.	Brandtzaeg, P., Secretory IgA: Designed for Anti-Microbial Defense. Frontiers in immunology 2013, 4, 222. DOI: 10.3389/fimmu.2013.00222.
3.	Corthesy, B., Multi-faceted functions of secretory IgA at mucosal surfaces. Frontiers in immunology 2013, 4. DOI: Artn 185
10.3389/Fimmu.2013.00185.
4.	Pabst, O., New concepts in the generation and functions of IgA. Nature reviews. Immunology 2012, 12 (12), 821-32. DOI: 10.1038/nri3322.
5.	Kaetzel, C. S.; Robinson, J. K.; Chintalacharuvu, K. R.; Vaerman, J. P.; Lamm, M. E., The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA. Proceedings of the National Academy of Sciences of the United States of America 1991, 88 (19), 8796-800.
6.	Horton, R. E.; Vidarsson, G., Antibodies and their receptors: different potential roles mucosal defense. Frontiers in immunology 2013, 4. DOI: Unsp 200
10.3389/Fimmu.2013.00200.
7.	Turula, H.; Wobus, C. E., The Role of the Polymeric Immunoglobulin Receptor and Secretory Immunoglobulins during Mucosal Infection and Immunity. Viruses 2018, 10 (5). DOI: 10.3390/v10050237.
8.	Yan, H. M.; Lamm, M. E.; Bjorling, E.; Huang, Y. T., Multiple functions of immunoglobulin A in mucosal defense against viruses: an in vitro measles virus model. Journal of virology 2002, 76 (21), 10972-10979. DOI: 10.1128/Jvi.76.21.10972-10979.2002.
9.	Zhou, D. H.; Zhang, Y.; Li, Q. L.; Chen, Y. Q.; He, B. X.; Yang, J. Y.; Tu, H. B.; Lei, L.; Yan, H. M., Matrix Protein-Specific IgA Antibody Inhibits Measles Virus Replication by Intracellular Neutralization. Journal of virology 2011, 85 (21), 11090-11097. DOI: 10.1128/Jvi.00768-11.
10.	Mazanec, M. B.; Kaetzel, C. S.; Lamm, M. E.; Fletcher, D.; Nedrud, J. G., Intracellular neutralization of virus by immunoglobulin A antibodies. Proceedings of the National Academy of Sciences of the United States of America 1992, 89 (15), 6901-5.
11.	Mazanec, M. B.; Nedrud, J. G.; Kaetzel, C. S.; Lamm, M. E., A three-tiered view of the role of IgA in mucosal defense. Immunology today 1993, 14 (9), 430-5. DOI: 10.1016/0167-5699(93)90245-G.
12.	Burns, J. W.; SiadatPajouh, M.; Krishnaney, A. A.; Greenberg, H. B., Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science 1996, 272 (5258), 104-107. DOI: DOI 10.1126/science.272.5258.104.
13.	Zhou, D. H.; Yang, Y.; Zhao, B. L.; Yu, J.; Cao, Y.; Yan, H.; Zhao, W.; Chen, L. Y.; Chen, F.; Li, X. D.; Zhang, E. J.; Yang, J. Y.; Zhong, M. H.; Chen, M. Z.; Hu, Q. X.; Deng, L.; Yan, H. M., IgA targeting on the alpha-molecular recognition element (alpha-MoRE) of viral phosphoprotein inhibits measles virus replication by interrupting formation and function of P-N complex intracellularly. Antiviral research 2018, 161, 144-153. DOI: 10.1016/j.antiviral.2018.11.014.
14.	Osada, N.; Kohara, A.; Yamaji, T.; Hirayama, N.; Kasai, F.; Sekizuka, T.; Kuroda, M.; Hanada, K., The genome landscape of the african green monkey kidney-derived vero cell line. DNA research : an international journal for rapid publication of reports on genes and genomes 2014, 21 (6), 673-83. DOI: 10.1093/dnares/dsu029.
15.	Desmyter, J.; Melnick, J. L.; Rawls, W. E., Defectiveness of Interferon Production and of Rubella Virus Interference in a Line of African Green Monkey Kidney Cells (Vero). J Virol 1968, 2 (10), 955-&.
16.	Devaux, P.; Priniski, L.; Cattaneo, R., The measles virus phosphoprotein interacts with the linker domain of STAT1. Virology 2013, 444 (1-2), 250-6. DOI: 10.1016/j.virol.2013.06.019.
17.	Devaux, P.; Hudacek, A. W.; Hodge, G.; Reyes-Del Valle, J.; McChesney, M. B.; Cattaneo, R., A recombinant measles virus unable to antagonize STAT1 function cannot control inflammation and is attenuated in rhesus monkeys. Journal of virology 2011, 85 (1), 348-56. DOI: 10.1128/JVI.00802-10.
18.	Heim, M. H.; Kerr, I. M.; Stark, G. R.; Darnell, J. E., Jr., Contribution of STAT SH2 groups to specific interferon signaling by the Jak-STAT pathway. Science 1995, 267 (5202), 1347-9.
19.	Fleming, S. B., Viral Inhibition of the IFN-Induced JAK/STAT Signalling Pathway: Development of Live Attenuated Vaccines by Mutation of Viral-Encoded IFN-Antagonists. Vaccines 2016, 4 (3). DOI: 10.3390/vaccines4030023.
20.	Schneider, W. M.; Chevillotte, M. D.; Rice, C. M., Interferon-stimulated genes: a complex web of host defenses. Annual review of immunology 2014, 32, 513-45. DOI: 10.1146/annurev-immunol-032713-120231.
21.	Leung, D. W., Mechanisms of Non-segmented Negative Sense RNA Viral Antagonism of Host RIG-I-Like Receptors. Journal of molecular biology 2019. DOI: 10.1016/j.jmb.2019.06.002.
22.	Kretschmer, S.; Lee-Kirsch, M. A., Type I interferon-mediated autoinflammation and autoimmunity. Current opinion in immunology 2017, 49, 96-102. DOI: 10.1016/j.coi.2017.09.003.
23.	Shaffer, J. A.; Bellini, W. J.; Rota, P. A., The C protein of measles virus inhibits the type I interferon response. Virology 2003, 315 (2), 389-97.
24.	Chinnakannan, S. K.; Nanda, S. K.; Baron, M. D., Morbillivirus v proteins exhibit multiple mechanisms to block type 1 and type 2 interferon signalling pathways. PloS one 2013, 8 (2), e57063. DOI: 10.1371/journal.pone.0057063.
25.	Andrejeva, J.; Childs, K. S.; Young, D. F.; Carlos, T. S.; Stock, N.; Goodbourn, S.; Randall, R. E., The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-beta promoter. Proceedings of the National Academy of Sciences of the United States of America 2004, 101 (49), 17264-9. DOI: 10.1073/pnas.0407639101.
26.	Cui, S.; Eisenacher, K.; Kirchhofer, A.; Brzozka, K.; Lammens, A.; Lammens, K.; Fujita, T.; Conzelmann, K. K.; Krug, A.; Hopfner, K. P., The C-terminal regulatory domain is the RNA 5 '-triphosphate sensor of RIG-I. Mol Cell 2008, 29 (2), 169-179. DOI: 10.1016/j.molcel.2007.10.032.
27.	Bellini, W. J.; Englund, G.; Rozenblatt, S.; Arnheiter, H.; Richardson, C. D., Measles virus P gene codes for two proteins. Journal of virology 1985, 53 (3), 908-19.
28.	Devaux, P.; Cattaneo, R., Measles virus phosphoprotein gene products: conformational flexibility of the P/V protein amino-terminal domain and C protein infectivity factor function. Journal of virology 2004, 78 (21), 11632-40. DOI: 10.1128/JVI.78.21.11632-11640.2004.
29.	Takeuchi, K.; Kadota, S. I.; Takeda, M.; Miyajima, N.; Nagata, K., Measles virus V protein blocks interferon (IFN)-alpha/beta but not IFN-gamma signaling by inhibiting STAT1 and STAT2 phosphorylation. FEBS Lett 2003, 545 (2-3), 177-82.
30.	Yokota, S.; Saito, H.; Kubota, T.; Yokosawa, N.; Amano, K.; Fujii, N., Measles virus suppresses interferon-alpha signaling pathway: suppression of Jak1 phosphorylation and association of viral accessory proteins, C and V, with interferon-alpha receptor complex. Virology 2003, 306 (1), 135-46.
31.	Caignard, G.; Bourai, M.; Jacob, Y.; Infection, M. p. I. M. A. P.; Tangy, F.; Vidalain, P. O., Inhibition of IFN-alpha/beta signaling by two discrete peptides within measles virus V protein that specifically bind STAT1 and STAT2. Virology 2009, 383 (1), 112-20. DOI: 10.1016/j.virol.2008.10.014.
32.	Ramachandran, A.; Parisien, J. P.; Horvath, C. M., STAT2 is a primary target for measles virus V protein-mediated alpha/beta interferon signaling inhibition. Journal of virology 2008, 82 (17), 8330-8. DOI: 10.1128/JVI.00831-08.
33.	Palosaari, H.; Parisien, J. P.; Rodriguez, J. J.; Ulane, C. M.; Horvath, C. M., STAT protein interference and suppression of cytokine signal transduction by measles virus V protein. Journal of virology 2003, 77 (13), 7635-44.
34.	Ohno, S.; Ono, N.; Takeda, M.; Takeuchi, K.; Yanagi, Y., Dissection of measles virus V protein in relation to its ability to block alpha/beta interferon signal transduction. The Journal of general virology 2004, 85 (Pt 10), 2991-9. DOI: 10.1099/vir.0.80308-0.
35.	Childs, K.; Randall, R.; Goodbourn, S., Paramyxovirus V Proteins Interact with the RNA Helicase LGP2 To Inhibit RIG-I-Dependent Interferon Induction. Journal of virology 2012, 86 (7), 3411-3421. DOI: 10.1128/Jvi.06405-11.
36.	Devaux, P.; von Messling, V.; Songsungthong, W.; Springfeld, C.; Cattaneo, R., Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation. Virology 2007, 360 (1), 72-83. DOI: 10.1016/j.virol.2006.09.049.
37.	Caignard, G.; Guerbois, M.; Labernardiere, J. L.; Jacob, Y.; Jones, L. M.; Infectious Mapping Project, I. M.; Wild, F.; Tangy, F.; Vidalain, P. O., Measles virus V protein blocks Jak1-mediated phosphorylation of STAT1 to escape IFN-alpha/beta signaling. Virology 2007, 368 (2), 351-62. DOI: 10.1016/j.virol.2007.06.037.
38.	Desfosses, A.; Milles, S.; Jensen, M. R.; Guseva, S.; Colletier, J. P.; Maurin, D.; Schoehn, G.; Gutsche, I.; Ruigrok, R. W. H.; Blackledge, M., Assembly and cryo-EM structures of RNA-specific measles virus nucleocapsids provide mechanistic insight into paramyxoviral replication. Proceedings of the National Academy of Sciences of the United States of America 2019. DOI: 10.1073/pnas.1816417116.
39.	Calzas, C.; Chevalier, C., Innovative Mucosal Vaccine Formulations Against Influenza A Virus Infections. Frontiers in immunology 2019, 10, 1605. DOI: 10.3389/fimmu.2019.01605.
40.	Pattyn, J.; Van Keer, S.; Tjalma, W.; Matheeussen, V.; Van Damme, P.; Vorsters, A., Infection and vaccine-induced HPV-specific antibodies in cervicovaginal secretions. A review of the literature. Papillomavirus research 2019, 8, 100185. DOI: 10.1016/j.pvr.2019.100185.
41.	Kohler, G.; Milstein, C., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256 (5517), 495-7.






Figure 1. 7F1-IgA Inhibits MV Replication in Caco-2 Cells but not in Vero-pIgR Via Intracellular Neutralization
Vero-pIgR or Caco-2 cells grown in transwell were infected with MV at an MOI of 1. 20 μg of 7F1-IgA, 1D11-IgA or irrelevant antibody control in 120 μl of DMEM was added into basal chambers, and medium alone was added as a blank control. Cell lysates were collected at different time points after initial exposure to virus, and virus titers were assessed by plaque assay. (A) Virus titers of Vero-pIgR cell at 48 h.p.i. with different antibody doses. (B) Virus titers of Caco-2 cell at 72 h.p.i with different antibody doses. (C) Virus titers of Caco-2 cell infected with MV at different MOI at 72 h.p.i.. (D) Virus titers of Caco-2 cell at 0, 24, 48 and 72 h.p.i.. All the experiments were performed at least 3 times Data are represented as mean±SD, ns, not statistically significant; *P < 0.05; **P < 0.01; ***P < 0.001 (two-way ANOVA assay).

Figure 2. 7F1-IgA Reinforces IFN Responses in MV-infected Caco-2 Cells
Monolayers of Vero-pIgR or Caco-2 cells grown in transwell were infected with MV at an MOI of 1. 20 μg of 7F1-IgA, irrelevant antibody, or 120 μl medium as control were added to basal chambers. Supernatants were collected and assessed by IFN-β ELISA kit. (A) IFN-β concentrations in supernatants at different time points after MV infection of Vero-pIgR cells (0, 24 and 48 h.p.i.) and Caco-2 cells (0, 24, 48 and 72 h.p.i.). The dotted line indicates the limit of detection (LOD). (B) q-PCR analysis of mRNA levels of IFN-β, ISG15 and PKR in Caco-2 cell lysates at 0, 24, 48, and 72 h.p.i. All the experiments were performed at least 3 timesData are represented as mean±SD, ***P < 0.001 (two-way ANOVA assay).

Figure 3. Interaction between 7F1-IgA and MV P Sets JAK1 and STAT1 Free from Binding by MV P, and Makes More JAK1 and STAT1 toBe Phosphorylated in MV-infected Caco-2 Cells
Caco-2 cells grown in transwell were infected with MV at an MOI of 1. 20 μg of 7F1-IgA, irrelevant antibody, or medium alone control in 120 μl, was added at 48 h.p.i. At 60 h.p.i, cell lysates were analyzed by (A) western blotting, MV P, IgA κchain, PIRH2, MDA5, Tyk2, JAK1, p-JAK1, STAT1 and p-STAT1 detected with specific antibodies, respectively, and (B) immunoprecipitation with 8C4-IgG and analyzed via western blotting for detection of MV P, IgA κchain, PIRH2, MDA5, Tyk2, JAK1,p-JAK1,STAT1 and p-STAT1.

Figure 4. 7F1-IgA Confers MV-infected Caco-2 Cells Earlier and More Potent Phosphorylation of JAK1 and STAT1
Caco-2 cells grown in transwell were infected with MV at an MOI of 1. 20 μg of 7F1-IgA, irrelevant antibody, or medium in 120 μl, was added to basal chambers. Cell lysates were prepared at -2 h (uninfected cell), 0 h, 12 h, 24 h, 36 h, 48 h, 60 h and 72 h after initial exposure to virus, followed by western blotting for detection of JAK1, p-JAK1, STAT1, p-STAT1, MV P and β-actin. The graph represents the intensity of proteins detected over the same protein detected in the control condition (uninfected cell(-2 h.p.i) column in each panel).

Figure 5. 7F1-IgA Protects STAT1 from Binding by MV P and Facilitates Nuclear Translocation of STAT1 in MV-infected Caco-2 Cells
Caco-2 cells grown in transwell were infected with MV at an MOI of 1. 20 μg of 7F1-IgA, irrelevant antibody, or medium in 120 μl, was added to basal chambers. Cell monolayers were fixed at 48 h.p.i and stained for immunofluorescence confocal microscopy. (A) Expression of STAT1 in uninfected Caco-2 cells with or without 1000 U/ml IFN β stimulation. (B) Distribution of STAT1 (green) and MV P (red) in MV-infected Caco-2 cells. Nuclei were stained with DAPI for localizing nuclear translocation of STAT1.

Figure 6. Binding of 7F1-IgA on MV P Prevents JAK1 and STAT1 from Binding by MV P and Recovers Efficient Phosphorylation of JAK1 and STAT1 in Reconstituted 293T Cells
(A-B) 293T cells were transfected with Flag-P, HA-JAK1 and IgA, or Flag-JAK1, HA-P, and IgA. Cell lysates were subjected to immunoprecipitation 36 h after transfection and analyzed by western blotting. (C) 293T cells were transfected with Flag-JAK1, HA-P or/and IgA for 36 h with IFN-β being added at 24 h after transfection. Lysates were prepared and subjected to immunoprecipitation followed by western blotting.

Supplemental Figure 1. Plasmid Map of pFB-Dual-CMA-EF1
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